Medtronic (NYSE:MDT) said today that it’s launching a study of dual anti-platelet therapy and its Resolute Onyx drug-eluting stent.
The 2,000-patient study is designed to compare a one-month course of aspirin and an anti-coagulant in conjunction with the Resolute Onyx device or the BioFreedom DES made by Biosensors International (PINK:BSNRY). The Resolute Onyx stent is made from a single strand of cobalt alloy, formed into a sinusoidal wave with a radio-opaque core, Medtronic said.
Get the full story at our sister site, Drug Delivery Business News.
